6628 — Transcenta Holding Share News
0.000.00%
Last trade - 00:00- HK$274.26m
- HK$418.66m
- CNY7.44m
Brief: Transcenta Holding Says TST003 Received Ind Clearance From U.S. Food And Drug Administration
Brief: Transcenta Says Received IND Clearance From FDA For Its First-In-Class Gremlin1 Targeting Antibody TST003 For The Treatment Of Solid Tumors
Brief: Transcenta Holding Limited - Loss And Total Comprehensive Expenses For Six Months Rmb210.1 Million Versus Loss Of Rmb994.3 Million
Brief: Transcenta Holding Says Michael Ming Shi Will No Longer Serve As Executive Director
Brief: Transcenta Holding Says Albert Da Zhu, Executive Director Passed Away
Brief: Transcenta Says Unit Successfully Passed Audit Of European Union Qualified Person For Manufacturing Of Tst001
Brief: Transcenta Says Global Clinical Collaboration With Bristol Myers Squibb To Evaluate Tst001 In With Opdivo
Brief: Transcenta Holding Says Xiaolu Weng Appointed As An Executive Director
Brief: Transcenta Posts FY Adjusted Loss And Total Comprehensive Expenses RMB485.0 Mln
Brief: Transcenta Names Xiaolu Weng As CFO
Brief: Transcenta Holding Says Made A Successful Online Bid
Brief: Transcenta Says Ind Application Accepted By Nmpa For Pd-L1/Tgf-Β Bi-Functional Antibody Tst005
Biotech firm Transcenta, Dongguan Rural Commercial Bank sink in Hong Kong debut